# Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

> **NCT03229200** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Pharmacyclics Switzerland GmbH** · enrollment: 297 (actual)

## Conditions studied

- Lymphoma, B-Cell
- Lymphoma, Non-Hodgkin
- Leukemia, B-cell
- Graft Vs Host Disease
- Solid Tumor

## Interventions

- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03229200
- **Lead sponsor:** Pharmacyclics Switzerland GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-05-22
- **Primary completion:** 2027-05-10
- **Final completion:** 2027-05-10
- **Target enrollment:** 297 (ACTUAL)
- **Last updated:** 2025-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03229200

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03229200, "Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03229200. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*